→ David Chang and Arie Belldegrun are back in the business of building manufacturing facilities. Their startup Allogene $ALLO has inked a deal to build a state-of-the-art cell therapy manufacturing site in Newark, CA. That may sound a bit mundane in the world of drug development, but it’s critical to the company’s longterm success — as the two founders learned starting Kite.
One of the best funded biotech startups in the class of 2018, Allogene is adding a 118,000-square-foot facility at the Gateway 84 Silicon Valley advanced manufacturing campus. The company also plans to continue using a CMO for added production of their off-the-shelf CAR-Ts, which they believe is on track to supplant the two pioneering personalized CAR-Ts on the market.
→ Inovio is spinning out a startup biotech that will jump into the neoantigen field. Geneos Therapeutics will start out with platform tech from Inovio and $10.5 million in launch money from a Series A round led by Santé Ventures. The biotech is based in Plymouth Meeting, PA.
→ Novo Nordisk and Abbott are integrating their products to give diabetics a better view of their insulin and glucose data together as they manage their disease. These new digital initiatives are all the rage these days.
→ Amgen, Cytokinetics and Servier have launched their second Phase III study of omecamtiv for heart failure patients.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.Free Subscription